Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
 Back to Details

Connection

Michael Bristow to Cardiomyopathy, Dilated

This is a "connection" page, showing publications Michael Bristow has written about Cardiomyopathy, Dilated.

 
Connection Strength
  
 
 
6.968
  
  1. Altman NL, Gill EA, Kahwash R, Meyer LK, Wagner JA, Karimpour-Fard A, Berning AA, Minobe WA, Carroll IA, Jonas ER, Slavov D, Emani S, Abraham WT, Gollah AR, Ellis SL, Taylor MRG, Graw SL, Mestroni L, McKinsey TA, Buttrick PM, Kao DP, Bristow MR. Heart Rate Reduction Is Associated With Reverse Left Ventricular Remodeling and Mechanism-Specific Molecular Phenotypes in Dilated Cardiomyopathy. Circ Heart Fail. 2025 Apr; 18(4):e012484.
    View in: PubMed
    Score: 0.740
  2. Tatman PD, Kao DP, Chatfield KC, Carroll IA, Wagner JA, Jonas ER, Sucharov CC, Port JD, Lowes BD, Minobe WA, Huebler SP, Karimpour-Fard A, Rodriguez EM, Liggett SB, Bristow MR. An extensive ?1-adrenergic receptor gene signaling network regulates molecular remodeling in dilated cardiomyopathies. JCI Insight. 2023 08 22; 8(16).
    View in: PubMed
    Score: 0.665
  3. Sucharov CC, Kao DP, Port JD, Karimpour-Fard A, Quaife RA, Minobe W, Nunley K, Lowes BD, Gilbert EM, Bristow MR. Myocardial microRNAs associated with reverse remodeling in human heart failure. JCI Insight. 2017 01 26; 2(2):e89169.
    View in: PubMed
    Score: 0.422
  4. Lindenfeld J, Cleveland JC, Kao DP, White M, Wichman S, Bristow JC, Peterson V, Rodegheri-Brito J, Korst A, Blain-Nelson P, Sederberg J, Hunt SA, Gilbert EM, Ambardekar AV, Minobe W, Port JD, Bristow MR. Sex-related differences in age-associated downregulation of human ventricular myocardial ?1-adrenergic receptors. J Heart Lung Transplant. 2016 Mar; 35(3):352-361.
    View in: PubMed
    Score: 0.386
  5. Kao DP, Lowes BD, Gilbert EM, Minobe W, Epperson LE, Meyer LK, Ferguson DA, Volkman AK, Zolty R, Borg CD, Quaife RA, Bristow MR. Therapeutic Molecular Phenotype of ?-Blocker-Associated Reverse-Remodeling in Nonischemic Dilated Cardiomyopathy. Circ Cardiovasc Genet. 2015 Apr; 8(2):270-83.
    View in: PubMed
    Score: 0.368
  6. Port JD, Bristow MR. Aptamer therapy for heart failure? Circ Res. 2011 Oct 14; 109(9):982-3.
    View in: PubMed
    Score: 0.292
  7. Calalb MB, McKinsey TA, Newkirk S, Huynh K, Sucharov CC, Bristow MR. Increased phosphorylation-dependent nuclear export of class II histone deacetylases in failing human heart. Clin Transl Sci. 2009 Oct; 2(5):325-32.
    View in: PubMed
    Score: 0.254
  8. Movsesian MA, Bristow MR. Alterations in cAMP-mediated signaling and their role in the pathophysiology of dilated cardiomyopathy. Curr Top Dev Biol. 2005; 68:25-48.
    View in: PubMed
    Score: 0.183
  9. Martin TG, Pak H, Gerhard GS, Merali S, Merali C, Lemster B, Dubey P, McTiernan CF, Bristow MR, Feldman AM, Kirk JA. Dysregulated Autophagy and Sarcomere Dysfunction in Patients With Heart Failure With Co-Occurrence of P63A and P380S BAG3 Variants. J Am Heart Assoc. 2023 12 19; 12(24):e029938.
    View in: PubMed
    Score: 0.170
  10. Abraham WT, Gilbert EM, Lowes BD, Minobe WA, Larrabee P, Roden RL, Dutcher D, Sederberg J, Lindenfeld JA, Wolfel EE, Shakar SF, Ferguson D, Volkman K, Linseman JV, Quaife RA, Robertson AD, Bristow MR. Coordinate changes in Myosin heavy chain isoform gene expression are selectively associated with alterations in dilated cardiomyopathy phenotype. Mol Med. 2002 Nov; 8(11):750-60.
    View in: PubMed
    Score: 0.157
  11. Lowes BD, Gilbert EM, Abraham WT, Minobe WA, Larrabee P, Ferguson D, Wolfel EE, Lindenfeld J, Tsvetkova T, Robertson AD, Quaife RA, Bristow MR. Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N Engl J Med. 2002 May 02; 346(18):1357-65.
    View in: PubMed
    Score: 0.152
  12. Purmah Y, Cornhill A, Lei LY, Dykstra S, Mikami Y, Satriano A, Labib D, Flewitt J, Rivest S, Sandonato R, Seib M, Howarth AG, Lydell CP, Heydari B, Merchant N, Bristow M, Kolman L, Fine NM, White JA. Mid-wall striae fibrosis predicts heart failure admission, composite heart failure events, and life-threatening arrhythmias in dilated cardiomyopathy. Sci Rep. 2022 02 02; 12(1):1739.
    View in: PubMed
    Score: 0.149
  13. Gao S, Mumme-Monheit A, Chen SN, Spector EB, Slavov D, Baralle FE, Bristow MR, Mestroni L, Taylor MRG. An LMNA synonymous variant associated with severe dilated cardiomyopathy: Case report. Am J Med Genet A. 2022 02; 188(2):600-605.
    View in: PubMed
    Score: 0.146
  14. Hailu FT, Karimpour-Fard A, Toni LS, Bristow MR, Miyamoto SD, Stauffer BL, Sucharov CC. Integrated analysis of miRNA-mRNA interaction in pediatric dilated cardiomyopathy. Pediatr Res. 2022 07; 92(1):98-108.
    View in: PubMed
    Score: 0.142
  15. Bristow MR. What type of beta-blocker should be used to treat chronic heart failure? Circulation. 2000 Aug 01; 102(5):484-6.
    View in: PubMed
    Score: 0.135
  16. Haywood ME, Cocciolo A, Porter KF, Dobrinskikh E, Slavov D, Graw SL, Reece TB, Ambardekar AV, Bristow MR, Mestroni L, Taylor MRG. Transcriptome signature of ventricular arrhythmia in dilated cardiomyopathy reveals increased fibrosis and activated TP53. J Mol Cell Cardiol. 2020 02; 139:124-134.
    View in: PubMed
    Score: 0.130
  17. Quaife RA, Lynch D, Badesch DB, Voelkel NF, Lowes BD, Robertson AD, Bristow MR. Right ventricular phenotypic characteristics in subjects with primary pulmonary hypertension or idiopathic dilated cardiomyopathy. J Card Fail. 1999 Mar; 5(1):46-54.
    View in: PubMed
    Score: 0.122
  18. Sweet ME, Cocciolo A, Slavov D, Jones KL, Sweet JR, Graw SL, Reece TB, Ambardekar AV, Bristow MR, Mestroni L, Taylor MRG. Transcriptome analysis of human heart failure reveals dysregulated cell adhesion in dilated cardiomyopathy and activated immune pathways in ischemic heart failure. BMC Genomics. 2018 Nov 12; 19(1):812.
    View in: PubMed
    Score: 0.119
  19. Zisman LS, Asano K, Dutcher DL, Ferdensi A, Robertson AD, Jenkin M, Bush EW, Bohlmeyer T, Perryman MB, Bristow MR. Differential regulation of cardiac angiotensin converting enzyme binding sites and AT1 receptor density in the failing human heart. Circulation. 1998 Oct 27; 98(17):1735-41.
    View in: PubMed
    Score: 0.119
  20. Myers VD, Gerhard GS, McNamara DM, Tomar D, Madesh M, Kaniper S, Ramsey FV, Fisher SG, Ingersoll RG, Kasch-Semenza L, Wang J, Hanley-Yanez K, Lemster B, Schwisow JA, Ambardekar AV, Degann SH, Bristow MR, Sheppard R, Alexis JD, Tilley DG, Kontos CD, McClung JM, Taylor AL, Yancy CW, Khalili K, Seidman JG, Seidman CE, McTiernan CF, Cheung JY, Feldman AM. Association of Variants in BAG3 With Cardiomyopathy Outcomes in African American Individuals. JAMA Cardiol. 2018 10 01; 3(10):929-938.
    View in: PubMed
    Score: 0.118
  21. Begay RL, Graw SL, Sinagra G, Asimaki A, Rowland TJ, Slavov DB, Gowan K, Jones KL, Brun F, Merlo M, Miani D, Sweet M, Devaraj K, Wartchow EP, Gigli M, Puggia I, Salcedo EE, Garrity DM, Ambardekar AV, Buttrick P, Reece TB, Bristow MR, Saffitz JE, Mestroni L, Taylor MRG. Filamin C Truncation Mutations Are Associated With Arrhythmogenic Dilated?Cardiomyopathy and Changes in?the Cell-Cell Adhesion Structures. JACC Clin Electrophysiol. 2018 04; 4(4):504-514.
    View in: PubMed
    Score: 0.113
  22. Leary PJ, Kronmal RA, Bluemke DA, Buttrick PM, Jones KL, Kao DP, Kawut SM, Krieger EV, Lima JA, Minobe W, Ralph DD, Tedford RJ, Weiss NS, Bristow MR. Histamine H2 Receptor Polymorphisms, Myocardial Transcripts, and Heart Failure (from the Multi-Ethnic Study of Atherosclerosis and Beta-Blocker Effect on Remodeling and Gene Expression Trial). Am J Cardiol. 2018 01 15; 121(2):256-261.
    View in: PubMed
    Score: 0.111
  23. Bristow MR, Abraham WT, Yoshikawa T, White M, Hattler BG, Crisman TS, Lowes BD, Robertson AD, Larrabee P, Gilbert EM. Second- and third-generation beta-blocking drugs in chronic heart failure. Cardiovasc Drugs Ther. 1997 May; 11 Suppl 1:291-6.
    View in: PubMed
    Score: 0.107
  24. Asano K, Dutcher DL, Port JD, Minobe WA, Tremmel KD, Roden RL, Bohlmeyer TJ, Bush EW, Jenkin MJ, Abraham WT, Raynolds MV, Zisman LS, Perryman MB, Bristow MR. Selective downregulation of the angiotensin II AT1-receptor subtype in failing human ventricular myocardium. Circulation. 1997 Mar 04; 95(5):1193-200.
    View in: PubMed
    Score: 0.106
  25. Quaife RA, Gilbert EM, Christian PE, Datz FL, Mealey PC, Volkman K, Olsen SL, Bristow MR. Effects of carvedilol on systolic and diastolic left ventricular performance in idiopathic dilated cardiomyopathy or ischemic cardiomyopathy. Am J Cardiol. 1996 Oct 01; 78(7):779-84.
    View in: PubMed
    Score: 0.103
  26. White M, Yanowitz F, Gilbert EM, Larrabee P, O'Connell JB, Anderson JL, Renlund D, Mealey P, Abraham WT, Bristow MR. Role of beta-adrenergic receptor downregulation in the peak exercise response in patients with heart failure due to idiopathic dilated cardiomyopathy. Am J Cardiol. 1995 Dec 15; 76(17):1271-6.
    View in: PubMed
    Score: 0.098
  27. Bristow MR, O'Connell JB, Gilbert EM, French WJ, Leatherman G, Kantrowitz NE, Orie J, Smucker ML, Marshall G, Kelly P, et al. Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Bucindolol Investigators. Circulation. 1994 Apr; 89(4):1632-42.
    View in: PubMed
    Score: 0.087
  28. Gilbert EM, Olsen SL, Renlund DG, Bristow MR. beta-adrenergic receptor regulation and left ventricular function in idiopathic dilated cardiomyopathy. Am J Cardiol. 1993 Mar 25; 71(9):23C-29C.
    View in: PubMed
    Score: 0.081
  29. Anderson FL, Port JD, Reid BB, Hanson G, Kralios AC, Hershberger RE, Bristow MR. Effect of therapeutic dopamine administration on myocardial catecholamine and neuropeptide Y concentrations in the failing ventricles of patients with idiopathic dilated cardiomyopathy. J Cardiovasc Pharmacol. 1992; 20(5):800-6.
    View in: PubMed
    Score: 0.074
  30. Bristow MR, Larrabee P, Minobe W, Roden R, Skerl L, Klein J, Handwerger D, Port JD, M?ller-Beckmann B. Receptor pharmacology of carvedilol in the human heart. J Cardiovasc Pharmacol. 1992; 19 Suppl 1:S68-80.
    View in: PubMed
    Score: 0.074
  31. Bristow MR, Anderson FL, Port JD, Skerl L, Hershberger RE, Larrabee P, O'Connell JB, Renlund DG, Volkman K, Murray J, et al. Differences in beta-adrenergic neuroeffector mechanisms in ischemic versus idiopathic dilated cardiomyopathy. Circulation. 1991 Sep; 84(3):1024-39.
    View in: PubMed
    Score: 0.073
  32. Gilbert EM, O'Connell JB, Bristow MR. Therapy of idiopathic dilated cardiomyopathy with chronic beta-adrenergic blockade. Heart Vessels Suppl. 1991; 6:29-39.
    View in: PubMed
    Score: 0.069
  33. Gilbert EM, Anderson JL, Deitchman D, Yanowitz FG, O'Connell JB, Renlund DG, Bartholomew M, Mealey PC, Larrabee P, Bristow MR. Long-term beta-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo. Am J Med. 1990 Mar; 88(3):223-9.
    View in: PubMed
    Score: 0.065
  34. Rasmussen RP, Minobe W, Bristow MR. Calcium antagonist binding sites in failing and nonfailing human ventricular myocardium. Biochem Pharmacol. 1990 Feb 15; 39(4):691-6.
    View in: PubMed
    Score: 0.065
  35. Sucharov C, Bristow MR, Port JD. miRNA expression in the failing human heart: functional correlates. J Mol Cell Cardiol. 2008 Aug; 45(2):185-92.
    View in: PubMed
    Score: 0.058
  36. Haddad GE, Saunders LJ, Crosby SD, Carles M, del Monte F, King K, Bristow MR, Spinale FG, Macgillivray TE, Semigran MJ, Dec GW, Williams SA, Hajjar RJ, Gwathmey JK. Human cardiac-specific cDNA array for idiopathic dilated cardiomyopathy: sex-related differences. Physiol Genomics. 2008 Apr 22; 33(2):267-77.
    View in: PubMed
    Score: 0.057
  37. Taylor MR, Slavov D, Ku L, Di Lenarda A, Sinagra G, Carniel E, Haubold K, Boucek MM, Ferguson D, Graw SL, Zhu X, Cavanaugh J, Sucharov CC, Long CS, Bristow MR, Lavori P, Mestroni L. Prevalence of desmin mutations in dilated cardiomyopathy. Circulation. 2007 Mar 13; 115(10):1244-51.
    View in: PubMed
    Score: 0.053
  38. Taylor MRG, Ku L, Slavov D, Cavanaugh J, Boucek M, Zhu X, Graw S, Carniel E, Barnes C, Quan D, Prall R, Lovell MA, Mierau G, Ruegg P, Mandava N, Bristow MR, Towbin JA, Mestroni L. Danon disease presenting with dilated cardiomyopathy and a complex phenotype. J Hum Genet. 2007; 52(10):830-835.
    View in: PubMed
    Score: 0.052
  39. Taylor MR, Slavov D, Gajewski A, Vlcek S, Ku L, Fain PR, Carniel E, Di Lenarda A, Sinagra G, Boucek MM, Cavanaugh J, Graw SL, Ruegg P, Feiger J, Zhu X, Ferguson DA, Bristow MR, Gotzmann J, Foisner R, Mestroni L. Thymopoietin (lamina-associated polypeptide 2) gene mutation associated with dilated cardiomyopathy. Hum Mutat. 2005 Dec; 26(6):566-74.
    View in: PubMed
    Score: 0.049
  40. Carniel E, Taylor MR, Sinagra G, Di Lenarda A, Ku L, Fain PR, Boucek MM, Cavanaugh J, Miocic S, Slavov D, Graw SL, Feiger J, Zhu XZ, Dao D, Ferguson DA, Bristow MR, Mestroni L. Alpha-myosin heavy chain: a sarcomeric gene associated with dilated and hypertrophic phenotypes of cardiomyopathy. Circulation. 2005 Jul 05; 112(1):54-9.
    View in: PubMed
    Score: 0.047
  41. Taylor MR, Fain PR, Sinagra G, Robinson ML, Robertson AD, Carniel E, Di Lenarda A, Bohlmeyer TJ, Ferguson DA, Brodsky GL, Boucek MM, Lascor J, Moss AC, Li WL, Stetler GL, Muntoni F, Bristow MR, Mestroni L. Natural history of dilated cardiomyopathy due to lamin A/C gene mutations. J Am Coll Cardiol. 2003 Mar 05; 41(5):771-80.
    View in: PubMed
    Score: 0.040
  42. Bohlmeyer T, Ferdensi A, Bristow MR, Takahashi S, Zisman LS. Selective activation of N-acyl-D-glucosamine 2-epimerase expression in failing human heart ventricular myocytes. J Card Fail. 2003 Feb; 9(1):59-68.
    View in: PubMed
    Score: 0.040
  43. Communal C, Colucci WS, Remondino A, Sawyer DB, Port JD, Wichman SE, Bristow MR, Singh K. Reciprocal modulation of mitogen-activated protein kinases and mitogen-activated protein kinase phosphatase 1 and 2 in failing human myocardium. J Card Fail. 2002 Apr; 8(2):86-92.
    View in: PubMed
    Score: 0.038
  44. Woulfe KC, Jeffrey DA, Pires Da Silva J, Wilson CE, Mahaffey JH, Lau E, Slavov D, Hailu F, Karimpour-Fard A, Dockstader K, Bristow MR, Stauffer BL, Miyamoto SD, Sucharov CC. Serum response factor deletion 5 regulates phospholamban phosphorylation and calcium uptake. J Mol Cell Cardiol. 2021 10; 159:28-37.
    View in: PubMed
    Score: 0.036
  45. Sinagra G, Di Lenarda A, Brodsky GL, Taylor MR, Muntoni F, Pinamonti B, Carniel E, Driussi M, Bristow MR, Mestroni L. Current perspective new insights into the molecular basis of familial dilated cardiomyopathy. Ital Heart J. 2001 Apr; 2(4):280-6.
    View in: PubMed
    Score: 0.035
  46. Gwathmey JK, Kim CS, Hajjar RJ, Khan F, DiSalvo TG, Matsumori A, Bristow MR. Cellular and molecular remodeling in a heart failure model treated with the beta-blocker carteolol. Am J Physiol. 1999 05; 276(5):H1678-90.
    View in: PubMed
    Score: 0.031
  47. Hinterberg MA, Kao DP, Bristow MR, Hunter LE, Port JD, G?rg C. Peax: interactive visual analysis and exploration of complex clinical phenotype and gene expression association. Pac Symp Biocomput. 2015; 419-30.
    View in: PubMed
    Score: 0.023
  48. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, Gilbert EM, Johnson MR, Goss FG, Hjalmarson A. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet. 1993 Dec 11; 342(8885):1441-6.
    View in: PubMed
    Score: 0.021
  49. Bristow MR, Minobe W, Rasmussen R, Larrabee P, Skerl L, Klein JW, Anderson FL, Murray J, Mestroni L, Karwande SV, et al. Beta-adrenergic neuroeffector abnormalities in the failing human heart are produced by local rather than systemic mechanisms. J Clin Invest. 1992 Mar; 89(3):803-15.
    View in: PubMed
    Score: 0.019
  50. Bristow MR, Feldman AM. Changes in the receptor-G protein-adenylyl cyclase system in heart failure from various types of heart muscle disease. Basic Res Cardiol. 1992; 87 Suppl 1:15-35.
    View in: PubMed
    Score: 0.019
  51. Bristow MR, Larrabee P, M?ller-Beckmann B, Minobe W, Roden R, Skerl L, Klein J, Handwerger D, Port JD. Effects of carvedilol on adrenergic receptor pharmacology in human ventricular myocardium and lymphocytes. Clin Investig. 1992; 70 Suppl 1:S105-13.
    View in: PubMed
    Score: 0.019
  52. Feldman AM, Ray PE, Silan CM, Mercer JA, Minobe W, Bristow MR. Selective gene expression in failing human heart. Quantification of steady-state levels of messenger RNA in endomyocardial biopsies using the polymerase chain reaction. Circulation. 1991 Jun; 83(6):1866-72.
    View in: PubMed
    Score: 0.018
  53. Feldman AM, Jackson DG, Bristow MR, Cates AE, Van Dop C. Immunodetectable levels of the inhibitory guanine nucleotide-binding regulatory proteins in failing human heart: discordance with measurements of adenylate cyclase activity and levels of pertussis toxin substrate. J Mol Cell Cardiol. 1991 Apr; 23(4):439-52.
    View in: PubMed
    Score: 0.018
  54. Movsesian MA, Bristow MR, Krall J. Ca2+ uptake by cardiac sarcoplasmic reticulum from patients with idiopathic dilated cardiomyopathy. Circ Res. 1989 Oct; 65(4):1141-4.
    View in: PubMed
    Score: 0.016
  55. Heilbrunn SM, Shah P, Bristow MR, Valantine HA, Ginsburg R, Fowler MB. Increased beta-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation. 1989 Mar; 79(3):483-90.
    View in: PubMed
    Score: 0.015
  56. Feldman AM, Cates AE, Veazey WB, Hershberger RE, Bristow MR, Baughman KL, Baumgartner WA, Van Dop C. Increase of the 40,000-mol wt pertussis toxin substrate (G protein) in the failing human heart. J Clin Invest. 1988 Jul; 82(1):189-97.
    View in: PubMed
    Score: 0.015
  57. Sam F, Kerstetter DL, Pimental DR, Mulukutla S, Tabaee A, Bristow MR, Colucci WS, Sawyer DB. Increased reactive oxygen species production and functional alterations in antioxidant enzymes in human failing myocardium. J Card Fail. 2005 Aug; 11(6):473-80.
    View in: PubMed
    Score: 0.012
  58. Fowler MB, Bristow MR. Rationale for beta-adrenergic blocking drugs in cardiomyopathy. Am J Cardiol. 1985 Apr 26; 55(10):120D-124D.
    View in: PubMed
    Score: 0.012
  59. McKillop JH, Bristow MR, Goris ML, Billingham ME, Bockemuehl K. Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity. Am Heart J. 1983 Nov; 106(5 Pt 1):1048-56.
    View in: PubMed
    Score: 0.011
  60. Noori A, Lindenfeld J, Wolfel E, Ferguson D, Bristow MR, Lowes BD. Beta-blockade in adriamycin-induced cardiomyopathy. J Card Fail. 2000 Jun; 6(2):115-9.
    View in: PubMed
    Score: 0.008
  61. Bowling N, Walsh RA, Song G, Estridge T, Sandusky GE, Fouts RL, Mintze K, Pickard T, Roden R, Bristow MR, Sabbah HN, Mizrahi JL, Gromo G, King GL, Vlahos CJ. Increased protein kinase C activity and expression of Ca2+-sensitive isoforms in the failing human heart. Circulation. 1999 Jan 26; 99(3):384-91.
    View in: PubMed
    Score: 0.008
  62. Movsesian MA, Smith CJ, Krall J, Bristow MR, Manganiello VC. Sarcoplasmic reticulum-associated cyclic adenosine 5'-monophosphate phosphodiesterase activity in normal and failing human hearts. J Clin Invest. 1991 Jul; 88(1):15-9.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)